Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus

Nina J. Karlin, Aaron Mangold, Shailja B. Amin, Heidi E. Kosiorek, Matthew R. Buras, Patricia M. Verona, Curtiss B. Cook

Research output: Contribution to journalArticle

Abstract

Aim: Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control. Materials & methods: Patients with melanoma with and without DM were matched 1:1 (2005-2016). Kaplan-Meier analysis was used to estimate overall survival and progression-free survival (PFS). Mixed models compared hemoglobin A 1c (HbA 1c ) and glucose measures over time. Results: Mean HbA 1c during the year after cancer diagnosis was 6.7%. The 5-year PFS rate was 89% (95% CI: 81-99%) for patients with DM and 63% (95% CI: 51-79%) for patients without DM (p = 0.02). Conclusion: Melanoma did not adversely impact glycemic control. The DM did not adversely impact survival of patients with melanoma, although increased PFS for melanoma was seen in individuals with DM. The objective of this study was to identify the effect of diabetes mellitus (DM) on survival of patients with melanoma and to determine whether melanoma and its treatment affected glycemic control. We used an institutional cancer registry to identify 112 patients with melanoma and grouped them by the presence (n = 56) or absence (n = 56) of DM. Patients were matched by age and year of melanoma diagnosis. For individuals with melanoma, DM did not decrease survival rates, and the diagnosis of melanoma did not affect glycemic control.

Original languageEnglish (US)
Article numberFSO368
JournalFuture Science OA
Volume5
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Melanoma
Diabetes Mellitus
Survival
Disease-Free Survival
Hemoglobin A
Survival Rate
Kaplan-Meier Estimate
Registries
Neoplasms
Glucose

Keywords

  • cancer
  • diabetes mellitus
  • endocrinology
  • glucose
  • malignancy
  • mortality
  • outcomes research

ASJC Scopus subject areas

  • Biotechnology

Cite this

Karlin, N. J., Mangold, A., Amin, S. B., Kosiorek, H. E., Buras, M. R., Verona, P. M., & Cook, C. B. (2019). Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus. Future Science OA, 5(3), [FSO368]. https://doi.org/10.4155/fsoa-2018-0084

Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus. / Karlin, Nina J.; Mangold, Aaron; Amin, Shailja B.; Kosiorek, Heidi E.; Buras, Matthew R.; Verona, Patricia M.; Cook, Curtiss B.

In: Future Science OA, Vol. 5, No. 3, FSO368, 01.01.2019.

Research output: Contribution to journalArticle

Karlin, NJ, Mangold, A, Amin, SB, Kosiorek, HE, Buras, MR, Verona, PM & Cook, CB 2019, 'Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus', Future Science OA, vol. 5, no. 3, FSO368. https://doi.org/10.4155/fsoa-2018-0084
Karlin, Nina J. ; Mangold, Aaron ; Amin, Shailja B. ; Kosiorek, Heidi E. ; Buras, Matthew R. ; Verona, Patricia M. ; Cook, Curtiss B. / Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus. In: Future Science OA. 2019 ; Vol. 5, No. 3.
@article{4a3ae4c5ef5b4438abbbe0db8a97bf96,
title = "Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus",
abstract = "Aim: Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control. Materials & methods: Patients with melanoma with and without DM were matched 1:1 (2005-2016). Kaplan-Meier analysis was used to estimate overall survival and progression-free survival (PFS). Mixed models compared hemoglobin A 1c (HbA 1c ) and glucose measures over time. Results: Mean HbA 1c during the year after cancer diagnosis was 6.7{\%}. The 5-year PFS rate was 89{\%} (95{\%} CI: 81-99{\%}) for patients with DM and 63{\%} (95{\%} CI: 51-79{\%}) for patients without DM (p = 0.02). Conclusion: Melanoma did not adversely impact glycemic control. The DM did not adversely impact survival of patients with melanoma, although increased PFS for melanoma was seen in individuals with DM. The objective of this study was to identify the effect of diabetes mellitus (DM) on survival of patients with melanoma and to determine whether melanoma and its treatment affected glycemic control. We used an institutional cancer registry to identify 112 patients with melanoma and grouped them by the presence (n = 56) or absence (n = 56) of DM. Patients were matched by age and year of melanoma diagnosis. For individuals with melanoma, DM did not decrease survival rates, and the diagnosis of melanoma did not affect glycemic control.",
keywords = "cancer, diabetes mellitus, endocrinology, glucose, malignancy, mortality, outcomes research",
author = "Karlin, {Nina J.} and Aaron Mangold and Amin, {Shailja B.} and Kosiorek, {Heidi E.} and Buras, {Matthew R.} and Verona, {Patricia M.} and Cook, {Curtiss B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.4155/fsoa-2018-0084",
language = "English (US)",
volume = "5",
journal = "Future Science OA",
issn = "2056-5623",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus

AU - Karlin, Nina J.

AU - Mangold, Aaron

AU - Amin, Shailja B.

AU - Kosiorek, Heidi E.

AU - Buras, Matthew R.

AU - Verona, Patricia M.

AU - Cook, Curtiss B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control. Materials & methods: Patients with melanoma with and without DM were matched 1:1 (2005-2016). Kaplan-Meier analysis was used to estimate overall survival and progression-free survival (PFS). Mixed models compared hemoglobin A 1c (HbA 1c ) and glucose measures over time. Results: Mean HbA 1c during the year after cancer diagnosis was 6.7%. The 5-year PFS rate was 89% (95% CI: 81-99%) for patients with DM and 63% (95% CI: 51-79%) for patients without DM (p = 0.02). Conclusion: Melanoma did not adversely impact glycemic control. The DM did not adversely impact survival of patients with melanoma, although increased PFS for melanoma was seen in individuals with DM. The objective of this study was to identify the effect of diabetes mellitus (DM) on survival of patients with melanoma and to determine whether melanoma and its treatment affected glycemic control. We used an institutional cancer registry to identify 112 patients with melanoma and grouped them by the presence (n = 56) or absence (n = 56) of DM. Patients were matched by age and year of melanoma diagnosis. For individuals with melanoma, DM did not decrease survival rates, and the diagnosis of melanoma did not affect glycemic control.

AB - Aim: Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control. Materials & methods: Patients with melanoma with and without DM were matched 1:1 (2005-2016). Kaplan-Meier analysis was used to estimate overall survival and progression-free survival (PFS). Mixed models compared hemoglobin A 1c (HbA 1c ) and glucose measures over time. Results: Mean HbA 1c during the year after cancer diagnosis was 6.7%. The 5-year PFS rate was 89% (95% CI: 81-99%) for patients with DM and 63% (95% CI: 51-79%) for patients without DM (p = 0.02). Conclusion: Melanoma did not adversely impact glycemic control. The DM did not adversely impact survival of patients with melanoma, although increased PFS for melanoma was seen in individuals with DM. The objective of this study was to identify the effect of diabetes mellitus (DM) on survival of patients with melanoma and to determine whether melanoma and its treatment affected glycemic control. We used an institutional cancer registry to identify 112 patients with melanoma and grouped them by the presence (n = 56) or absence (n = 56) of DM. Patients were matched by age and year of melanoma diagnosis. For individuals with melanoma, DM did not decrease survival rates, and the diagnosis of melanoma did not affect glycemic control.

KW - cancer

KW - diabetes mellitus

KW - endocrinology

KW - glucose

KW - malignancy

KW - mortality

KW - outcomes research

UR - http://www.scopus.com/inward/record.url?scp=85062993200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062993200&partnerID=8YFLogxK

U2 - 10.4155/fsoa-2018-0084

DO - 10.4155/fsoa-2018-0084

M3 - Article

AN - SCOPUS:85062993200

VL - 5

JO - Future Science OA

JF - Future Science OA

SN - 2056-5623

IS - 3

M1 - FSO368

ER -